<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357837</url>
  </required_header>
  <id_info>
    <org_study_id>116918</org_study_id>
    <secondary_id>2010-022556-23</secondary_id>
    <nct_id>NCT01357837</nct_id>
  </id_info>
  <brief_title>Assessment of GRT6005 in Painful Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized 4 Week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine whether GRT6005 is effective in patients with pain
      due to osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of 3 doses of
      GRT6005 taken once daily for 4 weeks in outpatients with moderate-to-severe painful
      osteoarthritis of the knee.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the pain intensity scores during the last week of the 4-week treatment period.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the 4 week treatment period.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of health as measured by Short Form-12 Health Survey</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response measured in percentage change of pain intensity since baseline.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leeds Sleep Evaluation Questionnaire to quantify subjective impressions of sleep and waking.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change (PGIC).</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician's Global Impression of Change (CGIC).</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly current pain intensity changes from baseline.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life EuroQoL-5 Dimension score, change from baseline.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Opioid Withdrawal Scale</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation from study due to treatment related adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to withdrawal from study</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily oral administration of matching placebo for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 µg GRT6005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral administration of GRT6005 for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 µg GRT6005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral administration of GRT6005 for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 µg GRT6005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral administration of GRT6005 for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>2 capsules of matching placebo once a day, in the morning, for a total of 28 days</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days</description>
    <arm_group_label>75 µg GRT6005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days</description>
    <arm_group_label>200 µg GRT6005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRT6005</intervention_name>
    <description>2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days</description>
    <arm_group_label>400 µg GRT6005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  painful Osteoarthritis of the knee based on American College of Rheumatology Criteria

          -  signed informed consent

          -  on stable analgesic medications for painful osteoarthritis with regular analgesic
             intake for at least 3 months

          -  pain intensity score of 4 or greater on the 11-point numeric rating scale (where 0
             indicates &quot;no pain&quot; and 10 indicates &quot;pain as bad as you can imagine&quot;).

        Exclusion Criteria:

          -  Substance Abuse

          -  Significant cardiac disease

          -  Presence of risk factors for Torsades de Pointes and chronic severe cardiac disease

          -  History of seizure disorder

          -  Chronic gastrointestinal disease

          -  Conditions that contribute and confound to the assessment of pain

          -  Surgery or painful procedure during or within 3 months of enrollment

          -  Cancer

          -  Subjects with impaired renal function

          -  Subjects with impaired hepatic function

          -  Female subjects who are breastfeeding

          -  History of chronic hepatitis B or C or human immunodeficiency virus infection, or
             presence of acute hepatitis A, B, or C within the past 3 months.

          -  Clinically relevant history of hypersensitivity or allergy to paracetamol, opioids or
             the excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Olas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Specjalistyczne Centrum Medyczne NZOZ NOWOMED,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 3604</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3605</name>
      <address>
        <city>Senftenberg</city>
        <zip>3541</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3603</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3602</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3601</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3203</name>
      <address>
        <city>Bialystok</city>
        <zip>15-337</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3202</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3208</name>
      <address>
        <city>Gdynia</city>
        <zip>81-834</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3206</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3207</name>
      <address>
        <city>Lublin</city>
        <zip>20-605</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3210</name>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3201</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3204</name>
      <address>
        <city>Warsawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3211</name>
      <address>
        <city>Warszawa</city>
        <zip>02-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3213</name>
      <address>
        <city>Wloszczowa</city>
        <zip>29-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3205</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3305</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3302</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3303</name>
      <address>
        <city>Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3312</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3308</name>
      <address>
        <city>Mérida.Badajoz.</city>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3310</name>
      <address>
        <city>Oviedo</city>
        <zip>33009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3311</name>
      <address>
        <city>Petrer (Alicante)</city>
        <zip>03610</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3304</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3306</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3313</name>
      <address>
        <city>Torrelavega (Cantabria)</city>
        <zip>39300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, knee</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Pain</keyword>
  <keyword>Painful</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

